News
Elon Musk’s Neuralink is a last chance at a normal life for some
Kate Kegans doesn’t own a Tesla or any other products from Elon Musk’s many entities. Still, his Neuralink program could be her last chance at a normal life after experiencing vision impairments nearly nine years ago.
“I started having double vision, especially when I looked down,” Kegans said about her initial symptoms in 2011. “I went to my ophthalmologist. He goofed around with contact lenses for a year with no improvement, so my General Physician recommended a specialist.” An MRI revealed a cavernous malformation on her brain stem, which sent her to a Brain and Spine specialist in Phoenix, Arizona.
After having one resection of the malformation in 2011, the issues didn’t resurface for three years, until the doctor who performed the first surgery performed another one in 2015. However, the 2015 surgery didn’t go all the way to completion after “unfavorable conditions” aborted the effort once the surgery began.
Kate then underwent a third surgery to attempt the resection of the cavernous malformation in July 2018. While doctors called this surgery a success, Kegans has not lived a normal life since. After the surgery, she began experiencing symptoms that came to be recognized as signs of complete hemi-body dysesthesia, which included freezing and burning sensations on the right side of her body, and the inability to feel temperature changes on that side, making her prone to burns and scalds.
“Honestly, at this point, I wish I had not done the procedure, and dealt with the ‘ticking time bomb’ instead,” she said. As a result, Kegans has been forced to look at nearly every option due to relatively no improvement in her condition.
“I have tried extensive surgical procedures to ‘fix’ this,” she told Teslarati. Kegans then outlined the extensive list of treatments that have come to no resolve for her issues. Everything from Deep Brain Stimulation (the process of sending electrical impulses to specific targets in the brain), an Intrathecal Catheter with PRIALT (a pump placed in the body with a direct line that delivers medication into the spinal fluid), multiple cingulotomies (a surgery where tissue in the anterior cingulate region of the brain is altered, creating a lesion), Gamma Knife Radiation (surgery that destroys precisely selected areas of tissue by using radiation and not a blade), and a mesencephalotomy (an ablative procedure which lesions the pain pathways at the midbrain level to treat pain), all have had no effect on her condition.
In fact, one surgery disrupted her vision, an issue that was eventually fixed with another episode that took Kegans under the knife in November 2019. After it was fixed, the mesencephalotomy, which took place in July 2020, disrupted her vision once again. After having another surgery just eight weeks ago to improve her vision, she states that it still has not been fixed.
After trying a non-surgical route through various medications, including ketamine infusions, medicinal marijuana, gabapentin, and naltrexone, Kegans has one more option, as she says she is desperate. “I am willing to try anything to get back to normal.”
Enter: Neuralink
In August 2020, Elon Musk unveiled the “Link v0.9,” Neuralink’s latest and greatest implant device aimed to begin the surge toward curing various neurological diseases. A few sassy pigs with Neuralink chips implanted in their brains were among the first publicly unveiled test subjects. One, in particular, Gertrude, was a great example of how Neuralink could be used to battle various neurological diseases, including the loss of limb function.
Elon Musk’s Neuralink unveils sleek V0.9 device, uses sassy pigs for live brain machine demo
The Neuralink implant was able to predict all the limb movements based on the neural activity that was being read. With all of the improvements and developments in the Neuralink chip, many became believers in Musk’s most recent endeavor. One of them, a friend of Kegans, who sent her information about the pigs from the demonstration.
“My friend, who is a nurse, sent me an article on Neuralink. They said that human trials would eventually start,” Kegans said.
Neuralink has a handful of problems that it plans to solve on the neurological spectrum of injuries. Everything from memory loss, to blindness, to paralysis, to seizures will be a target for the chip. Another one is extreme pain, something that Kegans experiences on a daily basis, and it has affected her ability to live a normal life for years.
“I am 57 years old,” she said. “I used to be very active, and I need help returning to a normal life. I have zero quality of life now, and I am willing to try anything to get back to normal.”
FDA Designation, and what lies ahead for Neuralink’s possible patients
In July, the Food and Drug Administration (FDA) gave Neuralink a “breakthrough device” designation, allowing the company to continue working with its Link v0.9. Eventually, the device could be sewn deeper into the brain, allowing for a wider variety of functions beyond the upper cortex. Some of the issues that could be solved would deal with addiction, depression, and motor function.
As of now, human trials are the next step for Neuralink to make some real noise in the medical sector. On February 1st, Musk gave an update regarding Neuralink’s development with the FDA, where he indicated the company was in constant communication with the federal agency to ensure implant safety.
Neuralink is working super hard to ensure implant safety & is in close communication with the FDA. If things go well, we might be able to do initial human trials later this year.
— Elon Musk (@elonmusk) February 1, 2021
After stating that human trials could begin as soon as this year, several people, Kegans included, reached out to talk about the possibility of being included in the first Neuralink trials. While no details are known yet, there are plenty of people out there who have been affected by severe brain injuries that have negatively altered their lives. Neuralink could be the key to eventually making neurological disorders a thing of the past, especially as the company plans to create a chip that will be affordable for virtually everyone.
Tesla CEO Elon Musk posted a photo of himself standing with the Optimus production team inside Tesla’s Fremont factory, arms crossed amid workers in hard hats and safety vests. The image captures a pivotal industrial shift: the same facility space once dedicated to building Tesla’s flagship Model S sedan and Model X SUV is now home to the company’s humanoid robot manufacturing line.
Walking the Optimus production line in Fremont pic.twitter.com/ABS0tuRibW
— Elon Musk (@elonmusk) July 1, 2026
Tesla’s Fremont Factory, acquired in 2010 from the former NUMMI joint venture between Toyota and GM, has been the company’s original U.S. manufacturing hub since Model S production began in 2012.
The Model X followed soon thereafter. These premium vehicles offered lower annual volumes, recently around 30,000 combined, compared to the high-volume Model 3 and Model Y lines that continue around the site. Over their combined run, the S and X accounted for roughly 610,000 units.
In late January 2026, during Tesla’s Q4 2025 earnings call, Elon Musk announced the end of Model S and Model X production in Q2 2026. The final vehicles rolled off the line in early May. Rather than retooling for another vehicle, Tesla chose to convert the dedicated S/X assembly area into a dedicated Optimus Gen 3 production line.
Model 3 and Y manufacturing remains unaffected. Tesla’s official Fremont Factory page now lists Optimus alongside the 3 and Y as core products.
The conversion was executed with remarkable speed. After production stopped, crews dismantled the existing vehicle line and installed entirely new modular equipment—including lines sourced from Germany and dozens of sub-lines for actuators, batteries, and other components—in roughly four months.
Musk described the timeline as “insanely fast,” noting it would be unprecedented for any other manufacturer. Initial Optimus output is expected to ramp slowly due to the robot’s roughly 10,000 unique parts and the brand-new production processes involved. The Fremont line targets an eventual capacity of 1 million Optimus units per year.
Tesla isn’t joking about building Optimus at an industrial scale: Here we go
Optimus Development Timeline
- August 19, 2021: Optimus (then called Tesla Bot) formally announced at Tesla’s first AI Day. A concept video showed a person in a suit demonstrating the vision for a general-purpose humanoid capable of dangerous, repetitive, or boring tasks using the same AI architecture as Full Self-Driving.
- 2022: Early prototypes displayed. At the second AI Day in September, semi-functional units demonstrated walking across a stage and basic arm movements
- 2023: September videos showed improved capabilities, including sorting colored blocks, precise limb awareness, and holding a Yoda pose.
- 2024-early 2025: Factory integration videos showed Optimus navigating workspaces and handling objects like battery cells.
- January 2026: Gen 3 mass-production activities began at Fremont, with reports of over 1,000 Gen 3 units already operating inside the factory for real-world learning and AI training
- April 2026: Musk confirms Optimus production on converted Fremont line would begin in late July or August 2026. The Gen 3 reveal, originally eyed for Q1, was pushed closer to production start. A second, much larger Optimus factory at Giga Texas is under construction, with volume production targeted for Summer 2027 and long-term capacity of 10 million units annually
- July 1, 2026: Musk’s on-site visit and team photo confirm the Optimus line is operational and the transition is actively progressing
Tesla positions Optimus as potentially its largest project ever, leveraging vertical integration, AI expertise, and car-like manufacturing know-how to scale humanoid robots first for its own factories and later for broader industrial and consumer use.
The Fremont conversion serves as a critical proving ground for this ambitious new chapter in Tesla’s already-rich history.
Investor's Corner
Tesla gets its latest short from Michael Burry: ‘Happy it jumped back to this level’
Tesla short seller Michael Burry, the subject of the film “The Big Short,” where he was portrayed by Steve Carell, has revealed he has opened a new bet against the stock.
In a new update to his Substack newsletter in a post titled “Trading Post June 30, 2026,” Burry revealed a new set of bets against Tesla, Caterpillar, NVIDIA, Applied Materials Inc., and the iShares Semiconductor ETF.
In regard to Tesla, Burry wrote:
“And finally I shorted Tesla at 416.22. Happy it jumped back to this level.”
This means Burry likely opened his new short position after the company’s recent rally on Wall Street, which saw Tesla shares sink in mid-May, only to recover to well over the $400 mark. Currently, shares trade at around $427.
The company saw a big Tuesday as shares climbed considerably, over 10 percent. The size of the Tesla short was not provided, nor did Burry give any information on the position’s structure, the number of shares, dollar value, or whether options were used in the short.
The Tesla and SpaceX merger everyone is talking about is quietly building
Over the years, Burry has been one of the more vocal critics of Tesla, calling its share price “media inflated,” and saying it was “ridiculously overvalued” as recently as December.
The company has largely transitioned away from being known as an automotive company and instead is much more widely regarded as an AI play, mostly due to its Full Self-Driving efforts, Optimus robot development, and data collection related to both.
This has not pulled those skeptics away from being vocal about their distaste for how Tesla is valued, but there’s no denying that the company is a global force in many things, including sustainable energy, automotive, and AI.
Wedbush Securities is initiating stock coverage on SpaceX (NASDAQ: SPCX), marking the first comments on the company since it went public several weeks ago. Wedbush and its analyst handling coverage, Dan Ives, are widely bullish on fellow Musk company Tesla (NASDAQ: TSLA).
Ives wrote his first note initiating coverage of SpaceX shares on Wednesday with a $190 price target and an ‘Outperform’ rating. The firm believes the company is well positioned off of its IPO because of its wide array of projects, including AI compute power and infrastructure, connectivity projects, and launches.
“We view SpaceX as one of the most differentiated assets within the tech market with a strong footprint across its three core markets, with Starlink driving success with connectivity,” Ives wrote, “Starship launches leading to a demand flywheel and increasing deal flow for its Colossus clusters.”
Elon Musk called it Epic: The full story of SpaceX’s Starship Flight 12
Wedbush leans heavily on Starlink, which they say is the “profitability driver given the strength of its recurring revenue base of ~12 million subscribers as of June 5th.” Ives believes Starlink is still in the “early innings” of penetrating the global telecommunications and broadband market, as it only holds less than a 1 percent share. However, this number is sure to increase over time.
It also highlights the importance of Starship, which it says is an “essential layer” of SpaceX’s overall success. SpaceX developing and displaying the ability to reuse rockets is a major cost and reliability advantage “as it reduces the necessary hardware launch costs while generating a feedback loop for future flights to improve their launch flight rate without accelerating capex spend.”
Finally, SpaceX’s recent AI/Compute projects are also very elementary, Ives writes. It is worth mentioning Wedbush said its $190 price target is derived from a valuation forecast that sees the company yielding roughly $2.48 trillion of implied enterprise value.
There are also some factors that Wedbush did not take into account with its initial coverage. The firm wrote in the note:
“We note that there is optional value coming from Starship’s accelerating scale towards sub-$200/kg unit economics, orbital data centers, and enterprise AI monetization as these factors could drive meaningful upside but these face major hurdles, so we do not take that into account with our valuation.”
SpaceX shares are down just over 2 percent today, trading at around $167 at the time of publication.
Tesla Optimus project fires up as Musk sees production line progress
Tesla gets its latest short from Michael Burry: ‘Happy it jumped back to this level’
